Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)
CNBG-REC-2022002
Phase 2 mab active
Quick answer
Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) for COVID-19 is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- mab
- Status
- active